CBD Oil Combined With Orphenadrine Dramatically Reduced Pain in a Patient With Mast Cell Activation Syndrome

A patient with severe, treatment-resistant pain from mast cell activation syndrome experienced an 87% reduction in pain interference after treatment with CBD oil and orphenadrine.

Russo, Marc A et al.·A&A practice·2025·Preliminary EvidenceCase Report
RTHC-07535Case ReportPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

A patient with widespread, severe, refractory MCAS pain was treated with orphenadrine and CBD oil. Pain severity reduced by 56% and pain interference by 87% at 20 weeks. CBD has recently been shown to suppress mast cell activation and degranulation.

Key Numbers

Pain severity reduced by 56%. Pain interference reduced by 87% at 20 weeks.

How They Did This

Single case report documenting treatment response over 20 weeks with standardized pain scales.

Why This Research Matters

MCAS causes chronic pain with no established treatment paradigm. This is the first reported case of using CBD's mast cell-suppressing properties specifically to target MCAS pain.

The Bigger Picture

If CBD's mast cell-suppressing properties can be confirmed in larger studies, it could offer a targeted treatment for a condition with limited options.

What This Study Doesn't Tell Us

Single case report. Cannot determine which component drove improvement. Natural disease fluctuation or placebo cannot be excluded.

Questions This Raises

  • ?Would CBD alone produce similar results?
  • ?What CBD dosing is optimal for mast cell suppression?
  • ?Could this approach help other mast cell conditions?

Trust & Context

Key Stat:
87% reduction in pain interference over 20 weeks
Evidence Grade:
Preliminary: single case report with no control or blinding.
Study Age:
Published in 2025.
Original Title:
A Treatment Approach for Severe Pain in Mast Cell Activation Syndrome: A Case Report.
Published In:
A&A practice, 19(12), e02115 (2025)
Database ID:
RTHC-07535

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

Can CBD help with mast cell activation syndrome?

This case report describes dramatic pain reduction in one MCAS patient treated with CBD oil. CBD has been shown to suppress mast cell activation, providing a possible mechanism.

How does CBD affect mast cells?

Recent research suggests CBD can suppress mast cell activation and degranulation. In this case, MCAS pain was reduced by 87% after CBD oil treatment.

Read More on RethinkTHC

Cite This Study

RTHC-07535·https://rethinkthc.com/research/RTHC-07535

APA

Russo, Marc A; Santarelli, Danielle M. (2025). A Treatment Approach for Severe Pain in Mast Cell Activation Syndrome: A Case Report.. A&A practice, 19(12), e02115. https://doi.org/10.1213/XAA.0000000000002115

MLA

Russo, Marc A, et al. "A Treatment Approach for Severe Pain in Mast Cell Activation Syndrome: A Case Report.." A&A practice, 2025. https://doi.org/10.1213/XAA.0000000000002115

RethinkTHC

RethinkTHC Research Database. "A Treatment Approach for Severe Pain in Mast Cell Activation..." RTHC-07535. Retrieved from https://rethinkthc.com/research/russo-2025-a-treatment-approach-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.